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Background: Neutrophil elastase (NE) is implicated in chronic obstructive pulmonary disease
(COPD). AZD9668 is a reversible and selective inhibitor of NE, well tolerated at doses of
60 mg bid during Phase I/IIa development.
Methods: This 12-week, randomised, double-blind, placebo-controlled, Phase IIb, trial
(NCT01023516), investigated the efficacy and safety of AZD9668 (60 mg bid) versus placebo
in patients with symptomatic COPD and a history of exacerbation receiving maintenance bude-
sonide/formoterol. Primary outcome variable: forced expiratory volume in one second (FEV1).
Secondary endpoints included: post-bronchodilator FEV1, pre- and post-bronchodilator forced
vital capacity, FEV6, forced expiratory flow between 25% and 75% of vital capacity and inspi-
ratory capacity; peak expiratory flow and FEV1 measured at home; EXAcerbations of Chronic
pulmonary disease Tool and Breathlessness, Cough and Sputum Scores; St George’s respiratory
questionnaire for COPD (SGRQ-C) scores; exacerbations; and safety assessments.
Results: Six hundred and fifteen patients were randomised: placebo (302), AZD9668 60 mg bid
(313). AZD9668 showed no effect on lung function: change in mean pre-bronchodilator FEV1
versus placebo was 0.01 L (95% confidence interval: 0.03, 0.05; pZ 0.533). AZD9668 did
not significantly improve respiratory signs and symptoms, SGRQ-C score or time to first exac-
erbation. Adverse events were similar for AZD9668 and placebo.
Conclusions: Three months’ treatment with AZD9668 did not improve lung function, respira-
tory signs and symptoms or SGRQ-C score when added to budesonide/formoterol maintenance
therapy in patients with COPD. In the absence of definitive biomarkers of short-term disease
progression, further research is needed to determine the optimal duration of studies to eval-
uate NE inhibitors as disease-modifying agents.
ª 2011 Elsevier Ltd. All rights reserved.2) 6776777; fax: þ48 (42) 6781176.
lodz.pl (P. Kuna).
1 Elsevier Ltd. All rights reserved.
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patients with COPD with a history of exacerbation receivingChronic obstructive pulmonary disease (COPD) is an
inflammatory lung disease characterised by chronic airflow
limitation that is not fully reversible, as well as pathological
changes in the lung,1 and is projected to rank fifth in terms
of its disease burden by 2030.2 As COPD is an irreversible
and progressive disease,3 therapies with the potential to
impact disease modification and slow progression are of
particular interest. However, evidence that pharmaco-
therapy can decrease the rate of decline of lung function is
limited,4 and it is generally accepted that current phar-
macotherapy does not substantially influence disease
progression. Therefore, there remains a need to explore
the possibility of novel therapeutic approaches to COPD.
Neutrophils are important inflammatory cells and are
a key component of many of the pathological features of
COPD.5 Neutrophil elastase (NE), a serine protease found in
high concentrations in neutrophils,6 is able to degrade
extracellular matrix and proteins and destroy the lung
parenchyma.5,7,8 Consequently, inhibition of NE may have
the potential to inhibit proteolytic lung destruction and
arrest or slow the progressive decline in lung function
characteristically associated with COPD and other
obstructive lung disease states. As NE also has potent pro-
inflammatory effects9,10 and effects on mucus
secretion11e13 and mucociliary clearance,14 an NE inhibitor
might also be expected to improve lung function, health-
related quality of life (HRQoL) and exacerbation profile,
even in the short term. Previous Phase II, proof-of-concept
studies investigating the NE inhibitor, AZD9668, in patients
with bronchiectasis15 and cystic fibrosis16 have provided
some support for this hypothesis (see below).
AZD9668 is an orally available, potent and selective inhib-
itor of human NE that has potential utility as a therapeutic
agent for inflammatory lung diseases, including COPD.17 The
safety and tolerability of AZD9668 and its pharmacokinetics
have been established in two healthy volunteer studies and
one study in COPD patients. All three studies showed that the
drugwaswell tolerated and therewas noevidenceof clinically
relevant, AZD9668-related changes in clinical chemistry,
haematology or electrocardiogram (ECG) parameters.17
In a proof-of-concept study investigating the efficacy of
AZD9668 60 mg bid in subjects with bronchiectasis, AZD9668
was well tolerated and resulted in significant improvements
in forced expiratory volume in one second (FEV1) and slow
vital capacity (SVC).15 However, in a cystic fibrosis (CF) study,
no effect of AZD9668 was demonstrated on lung function,
although AZD9668 decreased inflammation and was associ-
ated with a reduction in tissue degradation markers.16
This proof-of-concept study evaluated the short-term
efficacy and safety of AZD9668, versus placebo, in symp-
tomatic patients with COPD treated with maintenance
budesonide/formoterol and with a history of exacerbation.
Methods
Design
This was a 12-week, randomised, double-blind, placebo-
controlled, parallel group, multinational, Phase IIb proof-of-concept study (NCT01023516) conducted in symptomatic
maintenance budesonide/formoterol to determine whether
AZD9668 can lead to short-term improvements in lung
function, symptoms, HRQoL and exacerbation profile. The
study consisted of a 3- to 4-week run-in period to stabilise
all patients on the same maintenance therapy before
eligible patients were randomised to a 12-week treatment
period. The study was conducted at 79 centres across 6
countries.
Patients
The first patient was enrolled on 24 November 2009, and
the last patient completed the study on 18 August 2010.
Male or female patients, 40e80 years of age were eligible
for inclusion if they had a clinical diagnosis of COPD (as
assessed by the global initiative on obstructive lung disease
guidelines1) with symptoms for at least 1 year prior to study
entry and with at least 1 COPD exacerbation (requiring
a course of steroids and/or antibiotics) during the same
year (see Supplementary Files for further inclusion
criteria).
Exclusion criteria included: any relevant disease or
disorder which, in the opinion of the investigator, could
have influenced the results of the study or the patient’s
ability to participate in the study or could have put the
patient at risk (see Supplementary Files for further exclu-
sion criteria).
Patients were discontinued from the study if: they did
not comply with the study protocol; they were not
correctly enrolled; there was any risk to the patient as
judged by the investigator; patients were lost to follow-up;
they had an alanine aminotransaminase (ALT) or aspartate
aminotransaminase (AST) 3 upper limit of normal (ULN)
or evidence of haemolysis or a platelet count below
80 109/L; they withdrew their consent at any time during
the study.
Treatments
During the run-in period, all patients were standardised to
maintenance therapy with budesonide/formoterol (320 mg/
9 mg) bid (see Supplementary Files for other permitted
medications). Patients were then randomised (block size 4)
to treatment with AZD9668 (60 mg bid) or placebo for 12
weeks using computer-generated randomisation codes that
were assigned sequentially as patients became eligible.
Blinding was maintained through the use of matching
placebo tablets of the same appearance administered at
the same dosage as the AZD9668 tablets i.e. 2 tablets bid.
Patients took 2 tablets bid for 12 weeks with doses
approximately 12 hours apart.
Assessments
The primary efficacy endpoint was pre-bronchodilator FEV1
at clinic visits. Secondary efficacy endpoints included: post-
bronchodilator FEV1 at clinic visits; pre- and post-
bronchodilator forced vital capacity (FVC), FEV in 6 s
(FEV6), forced expiratory flow between 25% and 75% of vital
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visits; peak expiratory flow (PEF) and FEV1 measured by
patients at home in the morning and evening; EXAcerba-
tions of Chronic pulmonary disease Tool and Breathlessness,
Cough and Sputum Scale (BCSS) scores; sputum colour
assessed using the Bronkotest 5-point colour scale; use of
reliever medication, including symptom and reliever-free
days; exercise capacity (Incremental and Endurance
Shuttle Walk Tests [ISWT and ESWT]); HRQoL e St George’s
Respiratory Questionnaire for COPD (SGRQ-C); exacerba-
tions (defined as antibiotic use and/or systemic steroid use
[oral or parenteral] and/or emergency room treatment
and/or hospitalisation).
Safety endpoints included adverse events (AEs), clinical
laboratory evaluations, vital signs, 12-lead ECG and phys-
ical examinations.
Exploratory endpoints included the measurement of
urinary biomarkers including levels of desmosine (creati-
nine normalised).
Statistical analyses
A sample size of 300 patients in each group of patients was
considered sufficient to detect clinically relevant effects
on FEV1 and demonstrate an effect of 50 mL with 80%
power, at the 5% significance level with a 1-sided test.
This target treatment effect was selected to see an effect
size similar to that obtained with inhaled steroids in
COPD.
The efficacy analysis set included all patients who
received at least 1 dose of investigational product and for
whom post-dose efficacy data were available. The safety
analysis set included all patients who received at least 1
dose of investigational product and for whom any post-dose
data were available.
All efficacy analyses used the efficacy analysis set.
Exploratory analysis of urine free desmosine used the safety
analysis set. As this was an exploratory study, a 2-sided p-
value of <0.1 was considered statistically significant;
however, 2-sided 95% confidence intervals (CIs) were
calculated to show the precision of the data. There was no
adjustment for multiplicity. The two groups of patients
were compared using an analysis of covariance (ANCOVA)
model, with the baseline value as covariate and country
and treatment as fixed factors. Least squares means (LSMs)
were calculated for the end of treatment value for AZD9668
and placebo, using last observation carried forward, and
differences between the LSMs were reported with a 95% CI.
For diary card assessments, a similar ANCOVA analysis
was performed but with baseline defined as the average of
the last 10 days before randomisation, and the end of
treatment value as the average of the last available 6
weeks. Differences between LSMs were reported with
a 95% CI.
The time to first event-based COPD exacerbation was
analysed using a Cox-proportional hazards model, with
country as covariate. Hazard ratios (HR) and 95% CI for the
difference between AZD9668 and placebo were calculated
from the Cox-proportional hazards model. Time to first
exacerbation during the randomised treatment period was
described using a KaplaneMeier plot. All safety data were
summarised descriptively by frequency and percentage.Post-hoc analyses
Post-hoc analyses were carried out on the efficacy analysis
set to further understand whether treatment outcome
(changes in FEV1, SGRQ-C, BCSS and use of reliever medi-
cation) was influenced by baseline, demographic and clin-
ical phenotypic parameters. Routine sub-group analyses
included parameters such as gender, age, smoking status
and disease severity (graded by FEV1 % of predicted normal
at baseline). In an effort to approximate clinical pheno-
types within the overall population, exploratory analyses
based on parameters such as a bronchotest value of >2
(bronchiectasis-like subset classification) as well as BCSS
cough and sputum positives, e.g. baseline cough and
sputum score 2 (chronic bronchitic subset classification)
were conducted. Sub-group analyses were carried out by
adding fixed effects for sub-group and sub-group by treat-
ment interaction to the original ANCOVA models. Differ-
ence estimates were computed within each group and tests
of the significance of the interaction term carried out. p-
values of <0.05 for the interaction test and <0.1 for the
within group differences were used as an indication where
signals could be present, but were not taken to be
confirmatory.
Ethical aspects
The study was approved by an independent ethics
committee and was conducted in accordance with the
Declaration of Helsinki and the International Conference on
Harmonisation/Good Clinical Practice. Patients provided
their informed consent prior to inclusion in the study.
Safety data was reviewed throughout the duration of the
study by an independent safety review committee.Results
Patients
Of the 906 patients screened, 615 patients were rando-
mised to treatment: 302 patients received placebo and 313
patients received AZD9668 60 mg bid. The disposition of
patients is shown in Fig. 1. Compliance with AZD9668 60 mg
bid was high during the randomised treatment period
(mean compliance was 96% in the placebo group and 97% in
the AZD9668 60 mg bid group). Compliance with mainte-
nance medication was also high (mean compliance was 96%
for both placebo and AZD9668 60 mg bid groups). Over 90%
of the randomised patients completed the study and the
rates of and reasons for discontinuation were well balanced
between the two groups of patients. All patients received
at least one dose of the study treatment to which they were
randomised (safety analysis set). One patient in the
placebo group and one patient in the AZD9668 60 mg group
did not have post-dose efficacy data and were excluded
from the efficacy analysis set.
Overall, the two groups of patients were well balanced
for demographic and patient characteristics (Table 1).
Medical and surgical histories at enrolment were generally
consistent between the two treatment groups. The most
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Figure 1 Patient flow chart.
Table 1 Baseline demographic and clinical characteristics (safety analysis set).
Treatment group
Placebo (nZ 302) AZD9668 60 mg bid (nZ 313)
Age, years, median (range) 61 (41e79) 62 (42e80)
Gender, n (%)
Male 221 (73) 233 (74)
Female 81 (27) 80 (26)
Race, n (%)
White 300 (99) 310 (99)
Other 2 (1) 3 (1)
Weight, kg, median (range) 77 (47e157) 78 (40e170)
BMI, kg/m2, median (range) 26.53 (16.56e51.86) 26.93 (16.22e51.32)
Number of years since first
COPD diagnosis, mean (SD)
6.90 (5.86) 6.60 (5.48)
Smoking, n (%)
Current 132 (44) 144 (46)
Former 170 (56) 169 (54)
Number of pack years, mean (SD) 35 (16.00) 36 (16.90)
% Predicted FEV1, mean (SD) 53.73 (15.64) 54.86 (15.37)
% FEV1/FVC, mean (SD) 50.25 (11.19) 50.42 (11.24)
Months since last exacerbation, mean (SD) 5.20 (3.03) 5.10 (2.95)
Number of exacerbations in last 12 months, mean (SD) 1.20 (0.50) 1.20 (0.51)
Bid, twice daily; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second;
FVC, forced vital capacity; and SD, standard deviation.
534 P. Kuna et al.
AZD9668 in COPD patients on budesonide/formoterol 535common comorbidities included hypertension, myocardial
ischaemia (and cardiac disorders), diabetes mellitus (and
metabolic disorders) and musculoskeletal pain.
Efficacy
Primary efficacy endpoint
There was no significant difference between AZD9668
60 mg bid and placebo for pre-bronchodilator FEV1 at end
of treatment (placebo: 1.43 L, standard error of the mean
[SEM] 0.02; AZD9668: 1.45 L, SEM 0.02), with an estimate
difference of 0.01 L (95% CI: 0.03, 0.05; pZ 0.533)
(Fig. 2a; Table 1A, Supplementary Files).a
b
Figure 2 LSM differences and 95% CIs between AZD9668 and plac
function endpoints at end of treatment (up to Week 12).Secondary efficacy endpoints
Lung function
Analyses of post-bronchodilator FEV1 as well as pre- and
post-bronchodilator FVC, FEV6, FEF25e75% and IC showed no
significant difference between AZD9668 60 mg bid and
placebo (Fig. 2; Table 1A, Supplementary Files) and there
was no evidence that AZD9668 60 mg bid improved lung
function variables measured daily at home (Table 1A,
Supplementary Files).
Signs and symptoms
There were no significant differences between AZD9668
60 mg bid and placebo in changes in BCSS total scores orebo for (a) pre-bronchodilator and (b) post-bronchodilator lung
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Files) or in EXACT scores. Similarly, there were no
significant differences between AZD9668 60 mg bid and
placebo in daily reliever medication usage or symptom-
free and reliever-free days (Table 1A, Supplementary
Files). Nor was there any significant difference between
AZD9668 60 mg bid and placebo in the ISWT and ESWT,
although a slight numerical decrease in endurance time
was seen in the ESWT for patients in the AZD9668 60 mg
bid group compared with placebo (Table 1A,
Supplementary Files). A small numerical decrease (not
statistically significant) in sputum colour score was seen
in both groups by the end of treatment (Table 1A,
Supplementary Files).
HRQoL
There was no evidence that AZD9668 60 mg bid significantly
improved the HRQoL versus placebo as assessed by SGRQ-C
scores, although slight decreases in SGRQ-C overall score
and the 3 sub-domain scores were observed for both groups
of patients over the course of the study (Table 1A,
Supplementary Files).
EXAcerbations
The percentage of patients with on-treatment exacerba-
tions was low and consistent between the two groups of
patients (10% patients in the placebo group versus 7% of
patients in the AZD9668 60 mg bid group). Although the
calculated HR was <1 (HR, 0.74; 95% CI: 0.42, 1.29;
pZ 0.286), the KaplaneMeier plot shows that time to first
exacerbation was consistent between the two groups of
patients (Fig. 3).
Post-hoc analyses
No positive interactions were observed between sub-
groups and treatment outcome for the majority of post-
hoc analyses, either for routine patient groups or clinicalFigure 3 KaplaneMeier plot depicting time to first exphenotypic sub-groups. Please see Supplementary Files for
further information on the post-hoc analyses.
Safety
AEs
Overall, the number of patients reporting AEs was low and
consistent between the two groups of patients (21%
patients in the placebo group versus 17% patients in the
AZD9668 60 mg bid group). There were no deaths during the
treatment period and the incidence of serious AEs (SAEs)
and AEs leading to discontinuation of investigational
product was low (3% patients overall in both cases) and
balanced between the two groups (Table 2A in
Supplementary Files). Please see Supplementary Files for
further information on the safety analyses.
Exploratory biomarkers
Desmosine is releasedas a result of elastin degradation, a key
process in the destruction of lung matrix tissue associated
with COPD. It is found in the blood, sputum and urine 18 and
has been proposed as a biomarker of lungmatrix degradation
(COPD Foundation, Biomarker Qualification Workshop,
Bethesda, MD, January 27e28, 2011). The LSM values for
creatinine-normalised urine desmosine (free) at the end of
treatment were comparable between the placebo and
AZD9668 60 mg bid groups (placebo: 1.98 nmol/mmol, 95%
CI: 1.86, 2.11; AZD9668: 1.96 nmol/mmol, 95% CI: 1.83,
2.08). There was no evidence that AZD9668 60 mg bid
significantly improved the levels of normalised urine des-
mosine (free) versus placebo, with a ratio of AZD9668:pla-
cebo of 0.99 (95% CI: 0.91, 1.08; pZ 0.771).Discussion
This study was designed to evaluate relatively short-term
outcomes related to potential anti-inflammatory effects ofacerbation during the study period (up to Week 12).
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treatment with AZD9668, there were no consistent
improvements in the signs and symptoms of COPD, exercise
capacity, HRQoL (SGRQ-C), exacerbations or levels of urine
desmosine (free), for either the primary patient population
or several patient sub-groups evaluated during exploratory
analyses.
It is important to examine potential reasons for these
negative findings, including limitations of the study design,
and implications for future research in this area. One
potential limitation is that the study was of insufficient
duration to detect an effect from a therapy that does not
have evident short-term anti-inflammatory or bronchodi-
latory impact. Many of the key studies for licensed COPD
therapies have been of 12 weeks duration,19e21 and
a recent review on the impact of tiotropium on exacerba-
tions, designated a minimum study duration of 12 weeks for
inclusion,22 supporting the study length used here.
However, several literature reports on the impact of COPD
therapies on exacerbation rate are of at least six months
duration,23,24 and it is noted that the event rate during this
three month study was low.
It is also possible that the dose of AZD9668 used in this
study was too low to effectively inhibit NE in vivo. The dose
was selected on the basis of safety results obtained from
preclinical,25 and subsequent Phase I/IIa studies.15e17
However, the translation of ex vivo and in vitro analyses
to the in vivo pulmonary mileu of the COPD lung has
limitations.
Another potential drawback of this study was the deci-
sion not to stratify patients by GOLD1 disease stage at
baseline. In this study, a population encompassing GOLD
Stage II and III was chosen to limit population heterogeneity
and to maximise the likelihood of patients having viable
parenchyma, while still manifesting significant disease.
Even though analyses of FEV1 baseline related to outcomes
did not change overall conclusions for the studied pop-
ulation, it is unknown whether AZD9668 might have an
effect in milder or more severe patients with COPD, for
example GOLD Stage I or IV. Given the difficulty in targeting
those patients with the most active disease, future studies
of anti-inflammatory agents in COPD may be better served
by identifying a broader range of disease or identifying
particular phenotypes depending on the compound’s
mechanism of action.
Failure of AZD9668 to meet endpoints in this study may
have been due to failure of the drug to reach its site of
action. Previous analyses in patients with bronchiectasis
have suggested AZD9668 60 mg bid can enter the lung at
concentrations sufficient to inhibit NE,26 however, the
presence of AZD9668 in the lung does not guarantee its
efficacy. It is known that endogenous inhibitors of NE, such
as a-antitrypsin, can be inactivated by oxidants present in
lung tissue,27,28 and that the expression of cytochrome
P450s can be affected by inhaled pollutants.29 Given the
link between COPD and cigarette smoke,1 it is possible that
changes in the expression and function of these endogenous
enzymes could impact the activity of AZD9668 in the lung.
Alternatively, AZD9668 may be rapidly cleared from the
lung.30
The lack of effect of AZD9668 in COPD may also be
because the role of neutrophils in the pathogenesis of COPDis less significant than previously thought.31 Two recent
reports diminish the role of neutrophils in the development
of COPD, particularly in early stage disease.32,33 Alterna-
tively, the addition of an NE inhibitor like AZD9668 may
result in no additional benefit on top of that already gained
with inhaled corticosteroid/long-acting beta agonist main-
tenance therapy.
This study has provided valuable learnings and insights
as the goal of therapy becomes more focused on influencing
disease progression in addition to ameliorating the symp-
toms of COPD. One challenge is the identification of
appropriate endpoints to adequately assess newer, anti-
inflammatory agents that do not confer short-term benefits
to patients. Furthermore, identification of valid biomarkers
that reflect underlying disease activity and a better
understanding of the changes in biomarker levels that occur
during inflammation would help in interpreting the impact
of anti-inflammatory treatments in patients with COPD.
Improved animal and in vitro models of COPD pathogeneses
are also required to provide better vehicles for piloting
novel therapies and to give clearer indications of whether
such treatments might make a successful transition into
patients.
Conclusion
This proof-of-concept study revealed no evidence to
suggest that treatment for up to 12 weeks with AZD9668
60 mg bid, together with budesonide/formoterol as back-
ground maintenance therapy, led to improvements in lung
function, respiratory symptoms, HRQoL or exacerbation
profile in COPD. While questions regarding the short-term
efficacy of AZD9668 have been rigorously evaluated in this
population, the question of whether AZD9668 would have
benefit as an effective long-term medication remains
unanswered. Researchers need to invest further effort in
developing disease models of COPD, identifying biomarkers
of disease activity, understanding the dynamics of the
inflammatory process and selecting appropriate study
endpoints to fully understand the contributions to COPD
disease management that future novel agents may be able
to make. Further research is required to determine the
optimal duration of studies involving disease-modifying
therapeutics.
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